30
|
|
|
- れいな たなせ
- 1 years ago
- Views:
Transcription
1 30
2 i 30
3 ii 30 1 p. 1 2 p. 8 3 PRL p p SIADHp p p p TSH p p p p ACTH p PRL p p TSH p p p IgG4 p. 59 p. 60
4 1 30 I II 1 GH GH 75 g 2 2 IGF-1 C 3 3 MRI CT 4 III X 5 I II 1 2 GH 0.4 ng/ml GH GH GH GH GH GH TRH LHRH GH 3 IGF-1 4 GHRH GH
5 2 5 X X X heel pad 22 mm GH IGF-1 I 185 cm 175 cm II III IV I II IV 2SD
6 3 IGF-1 (ng/ml) Isojima T et al., 2012 Endocr J SD 2SD 2SD 2SD
7
8 5 I GH II 1 GH μg mg mg mg 2 GH mg mg
9 6 3 4 IGF g GH IGF-1 75 g GH 0.4 ng/ml IGF-1 75 g GH 0.4 ng/ml 2 1 IGF-1 GH 5 GH 1 ng/ml IGF-1
10 7 2 IGF-1 IGF ng/ml GH GH GH GH GH GH 6 IGF-1 GH GH 7 IGF-1 GH 1 3 MRI
11 8 30 I cm II 1 ACTH ACTH III III mg μg/dl ACTH ACTH IV 1 CRH CRH 100 μg ACTH 1.5 6
12 9 2 8 mg MRI ACTH C/P 2 CRH 3 10 I 1 I 2 II III IV I II III ACTH 10 CBG μg/ 100 μg/ mg 0.5 mg 3 μg/dl 5 μg/dl ACTH CYP3A4 1 mg 1.8 μg/dl 5 6 DDAVP 4 μg ACTH 1.5 DDAVP 7 8 mg 1/2 8 3 MRI MRI 9 MRI 10 ACTH C/P 2 CRH 3 ACTH
13 10 ACTH C/P 3 CRH 5 PRL I QOL II ACTH QOL ACTH ACTH mg mg 1 2 1/ β
14 mg mg mg/ mg/ β 1 60 mg mg mg 1 3 CYP3A μg/dl 1 2
15 12 PRL 30 PRL I II PRL 1 III PRL 1 1 PRL 2 2 TSH CT MRI PRL PRL PRL I II 1 PRL PRL PRL PRL PRL
16 13 1 PRL 1 1 PRL 2 PRL PRL PRL PRL PRL PRL PEG IgG PRL 2 PRL α- H2
17 14 PRL 1 PRL mg/ PRL 1 mg/ 2.5 mg/ PRL mg/ PRL PRL
18 15 30 I II 1 1 3,000 ml 40 ml/kg 2,000 ml/m mosm/kg ml/kg/min mosm/kg mosm/kg 1 III MRI T1 2 IV 1 2 V2 2 I II II
19
20 μg/ 60 μg/ μg/ μg/
21 18 SIADH 30 SIADH 3 SIADH I II meq/l mosm/kg mosm/kg 5 20 meq/l 6 7 III ng/ml/h 4 5 mg/dl 5 IV 1 2 3
22 19 I II 1 SIADH SSRI
23 20 SIADH kg ml 3 9 g/ 3/ meq/l ml/ meq/l meq/l 120 meq/l meq/l meq/l meq/l V2 30 mg V2 SIADH
24 21 30 I II ,000 ml 40 ml/kg 2,000 ml/m mosm/kg pg/ml mosm/kg 6 III IV V2 2 I II II III IV I II III 1 2 3
25 22
26 23 30 LH FSH) LH FSH α- β- I II 1 2 LH FSH III IV FSH LH V I II III V I II V SF-1 FSH LH β- α-
27
28 25 30 I II SD 1.5SD III 2 IV 3 4 McCune-Albright hcg LHRH hcg hmg rfsh 5 V GPR54 KISS-1 MKRN3 DLK1 1 I 2 III IV 2 I 1 II 1 III IV
29 26 I 1 1SD Tanner 2-3 Tanner 4-5 LH miu/ml LH miu/ml FSH miu/ml FSH miu/ml LH/FSH LH/FSH Tanner 2-3 LH miu/ml LH miu/ml FSH miu/ml FSH miu/ml LH/FSH LH/FSH
30 27 I II LHRH III 1 LHRH LHRH μg/kg μg/kg 6 LHRH 2 LHRH 1 LHRH BMI 3 SD 13
31 28 15 LHRH LH
32 29 TSH 30 TSH I II 1 T4 TSH Syndrome of Inappropriate Secretion of TSH; SITSH 2 3 TSHβ TSH III 1 TRH TSH TSH TSH 5 SITSH T4 T3 IgG TSH TSH IV β I II I II
33 30 TSH TSH TSH TSH TSH
34 31 30 I SD SD II GH 5 L-DOPA GHRP-2 6 7L-DOPA GH 6 ng/ml GHRP GH 16 ng/ml III GH 3 IGF I 1 II 2 2 I 2 I 1 3 II 1 1 I 1 2 III I 1 II 1 III 2 3 I 1 3 III 2
35 32 1 I 1 II 2 GH 3 ng/ml GHRP-2 10 ng/ml 2 I 2 I 1 3 II 1 GH 3 ng/ml GHRP-2 10 ng/ml GH 6 ng/ml GHRP-2 16 ng/ml SD ² ² DDAVP ² ² ² 7 GH GH GH GH 8 Tanner-Whitehouse-2 TW2 Greulich
36 33 & Pyle TW2 CASMAS Computer Aided Skeletal Maturity Assessment System 9 GH ICD-10 2 type IA IB type II 3SD GHRH GH GH IGF-1 IGFBP ng/ml GHRP-2 16 ng/ml 4 3 GHD I GH GH II GH GH SD catch up 1 III 1 kg mg 6 7 IV GH 4 6 C 1
37 V VI ml TW2 SD SD VII GHD 1 TSH T4 GH GH T4 T4 2 ACTH 3 4
38 QOL cm/ GH IGF-1 2SD IGF-1 GH
39 36 30 GH QOL / 1 PIT-1 GH QOL 1-3 I II 1 GH GHRP GH 3 ng/ml GHRP GH 9 ng/ml ( GH 8 III IGF I 1 2 II 1 2 GH 2 I 2 II 2 II 1 1 GH
40 37 GH 1 I 1 2 II 1 2 GH GH 1.8 ng/ml GHRP-2 9 ng/ml 2 I 2 II 2 II 1 1 GH GH 1.8 ng/ml GHRP-2 9 ng/ml GH 1 2 GH growth without GH 3 4 GH GHRP-2 L-DOPA GHRH 5 GH GH GH GH 6 GH 1 2 DDAVP 3 α- β- 4 7 GH GHRP-2 GH
41 38 8 GH GH GH GH 3 GHGH GH I GH GH QOL GH GH GH GH GH GH GH GH GH II GH GH GH 3 μg/kg / IGF-1 4 IGF-1 GH 1 mg/ GH 1 kg GH IGF-1 2 QOL GH III GH
42 39 1 GH T4 2 3 IGF-1 GH 4 GH 1 2 IGF-1 GH
43 40 ACTH 30 ACTH I II ACTH 2 4 ACTH CRH 100 μg 3 4 ACTH 5 5 ACTH 250 mg ACTH-Z Z 500 mg 3 III ACTH I 1 II 1 4 II ACTH 10 pg/ml ACTH ACTH CRH ACTH 3 18 μg/dl CRH ACTH ACTH 4 45 mg/dl 0.1 U/kg 0.05 U/kg
44 41 18 μg/dl 5 ACTH CRH 1 ACTH CRH ACTH ACTH ACTH ACTH ACTH I II /3 1/3 ACTH 5 10 mg/ mg/ mg/ 7.5 mg 2.5 mg 15 mg/ 10 mg 5 mg 20 mg/ 15 mg 5 mg 2 3 kg 0.12 mg III mg/ 100 mg 100 mg /24 1 2
45 42 3 ACTH
46 43 PRL 30 PRL I II 1 PRL 1 2 TRH TRH μg PRL 2 I II 1 2 PRL TRH PRL PRL
47 44 30 I II 1 LH FSH 2 LHRH 3 III Kallmann Kallmann MRI IV 1 I II 2 Kallmann LHRH
48 45 I hcg-rfsh hmg hcg hcg-rfsh hcg-rfsh II mg/ mg/ mg/ mg/ hcg- rfsh hmg 1 hcg rfsh hcg 1,500 3,000 / 2 rfsh / 2 hmg / 2 hcg-rfsh ng/dl hcg 5,000 / rfsh hmg
49 46 III 11.5 hcg-rfsh
50 47 I cm 145 cm 2.5SD 135 cm II 17β IGF mg/ 2 1/ mg mg/ mg/ mg 1/4 1/ III
51 I II mg/ Ovarian hyperstimulation syndrome OHSS
52 FSH hmg FSH rfsh hcg 5,000 10,000 hcg FSH 17 mm hcg 16 mm 4 hcg 1 2
53 50 TSH 30 TSH I II 1 T4 2 2 TSH TRH μg TSH III TSH nonthyroidal illness low T3 2 I 1 II I 1 II ) II T3 T4 nonthyroidal illness low T3 T4 TSH 3 TSH TSH TRH T3 120 TSH 4 5 TRH 1 TRH TSH TRH
54 51 TSH I II L-T4 T4 TSH μg μg/kg 1 L-T4 T3 T μg μg/kg 2 3 III 1 TSH L-T μg/ 1 2 TRH TSH
55 52 30 CT MRI I 3 II III 1 MRI 2 MRI MRI MRI GH IGF-1 PRL TSH FT4 ACTH LH FSH E IC
56 53 5 GH GH IC GH 1 IgG4
57 IgG4 I II III IgG
58 I 1 2 II MRI III empty sella I II I II
59 56 I II MRI 4 III 1 2 I II I II 1 2 3
60 57 I 1 2 II MRI 6 2 III 1 2 I 1 2 II I 1 2 II
61 mg/kg/ 2 3 MRI 4
62 59 IgG4 30 IgG4 I 1 2 II IgG4 2 6 IgG4 3 7 IgG4 4 III I II II I II II I II II mg/dl IgE 3 IgG4 10/HPF IgG4/IgG 40 4 IgG4 IgG4 IgG4 http //
63 60 COI 2 COI COI JCR
小児内分泌学会-03-プログラム.indd
10 2 8 30 9 55 SOP 2 P-044 P-045 2 P-046 :Frasier 1 1 1 1 1 1 2 2 1 1 2 P-047 GH 1 1 2 2 2 2 2 1 2 P-048 Bartter 1 1 1 1 2 1 2 P-049 SD IGF-1 GHD P-050-2SD GHD 1 2 2 2 1 2 P-051 GHD 1,2 1 1 1 1 1 2 2 3
2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742
MJR-35 34 1 1 a MRICT b 2Beecham r-afs 3 4 20 4 mg/ 20 40 5 6 2 1 2 3 44 mg/ 5 6 7 8 4 Gn-RH 742 9 10 11 12 1 20 60 1 1MJR-351 mg/ 0.25 2 Lot. No. 2MJR-352 mg/ 1 1 Lot. No. 3MJR-354 mg/ 1 2 Lot. No. 2
i ii iii iv v vi vii ( ー ー ) ( ) ( ) ( ) ( ) ー ( ) ( ) ー ー ( ) ( ) ( ) ( ) ( ) 13 202 24122783 3622316 (1) (2) (3) (4) 2483 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 11 11 2483 13
untitled
Contents 1. 2 2. 3 3. 7 4. 9 5. 14 6. 15 7. 17 8. 19 9. 21 1. growth hormone deficiency : GHD10,00015,000 2 2. 03 1GH T3T4 1 GHRHGHIH -CIGF-1 -CIGF-1 3 1 GHRH GHIH GH TSH LHFSH -C IGF-1 -C IGF-1 T3T4 4
20－121
20 121 150 1 20 121 1 HbA1C 1 2 2 HbA1C 3 2 4 5 HbA1C 1 HbA1C -NH2 -CHO HbA1C 1 1 HbA1C HbA1C HbA1C HbA1C HbA1C 120 HbA1C HbA1C 1 2 2 HbA1C 120 10 10 10 3 β β 1 1 GAD ICA 2 4 HbA1C 2 1 2 5 2 20 121 150
=PAS.. =.. =.... 1% 01% ] = = = = 4 (A/A 2 / /B ) 1 8 2n / n n 64 n 64 n ] ] 4
![=PAS.. =.. =.... 1% 01% ] = = = = 4 (A/A 2 / /B ) 1 8 2n / n n 64 n 64 n ] ] 4](/thumbs/91/107033392.jpg "=PAS.. =.. =.... 1% 01% ] = = = = 4 (A/A 2 / /B ) 1 8 2n / n n 64 n 64 n ] ] 4")
1 1 1 1.1 1.1.1 3 : 0: + : +0 : : } 40 40 40 = 3 35 35 (38 )? +0+7 30 35-0+0 38 38 +30 5 30 30 +20 16 16 1. [ ] 2. 3. 4. + = etc 1.1.2 Ru 1 2 1.2 1.2.1 =PAS.. =.. =.... 1% 01% ] 1.2.2 = = = = 4 (A/A 2
2
1 2 3 4 5 6 7 8 9 10 I II III 11 IV 12 V 13 VI VII 14 VIII. 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 _ 33 _ 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 VII 51 52 53 54 55 56 57 58 59
untitled
i ii iii iv v 43 43 vi 43 vii T+1 T+2 1 viii 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 a) ( ) b) ( ) 51
i
14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7
...J......1803.QX
5 7 9 11 13 15 17 19 21 23 45-1111 48-2314 1 I II 100,000 80,000 60,000 40,000 20,000 0 272,437 80,348 82,207 81,393 82,293 83,696 84,028 82,232 248,983 80,411 4,615 4,757 248,434 248,688 76,708 6,299
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 () - 1 - - 2 - - 3 - - 4 - - 5 - 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
入門ガイド
ii iii iv NEC Corporation 1998 v P A R 1 P A R 2 P A R 3 T T T vi P A R T 4 P A R T 5 P A R T 6 P A R T 7 vii 1P A R T 1 2 2 1 3 1 4 1 1 5 2 3 6 4 1 7 1 2 3 8 1 1 2 3 9 1 2 10 1 1 2 11 3 12 1 2 1 3 4 13
<4D6963726F736F667420506F776572506F696E74202D208376838C835B83938365815B835683878393312E707074205B8CDD8AB78382815B83685D>
i i vi ii iii iv v vi vii viii ix 2 3 4 5 6 7 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
SC-85X2取説
I II III IV V VI .................. VII VIII IX X 1-1 1-2 1-3 1-4 ( ) 1-5 1-6 2-1 2-2 3-1 3-2 3-3 8 3-4 3-5 3-6 3-7 ) ) - - 3-8 3-9 4-1 4-2 4-3 4-4 4-5 4-6 5-1 5-2 5-3 5-4 5-5 5-6 5-7 5-8 5-9 5-10 5-11
名称未設定
[ ( 20120719_eng_0211_new2.xml) ] [Class Name] [Super Classes] Any / [Sub Classes (2)] [Description] [ Page - 1 / 41 ] [ ( 20120719_eng_0211_new2.xml) ] [Class Name] [Super Classes] Any / / [Sub Classes
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)
(1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46
i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii
ito.dvi
1 2 1006 214 542 160 120 160 1 1916 49 1710 55 1716 1 2 1995 1 2 3 4 2 3 1950 1973 1969 1989 1 4 3 3.1 3.1.1 1989 2 3.1.2 214 542 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
262014 3 1 1 6 3 2 198810 2/ 198810 2 1 3 4 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 2... 2... 4... 5... 9... 9... 10... 10... 10... 10... 13 2... 13 3... 15... 15... 15... 16 4...
これわかWord2010_第1部_100710.indd
i 1 1 2 3 6 6 7 8 10 10 11 12 12 12 13 2 15 15 16 17 17 18 19 20 20 21 ii CONTENTS 25 26 26 28 28 29 30 30 31 32 35 35 35 36 37 40 42 44 44 45 46 49 50 50 51 iii 52 52 52 53 55 56 56 57 58 58 60 60 iv
パワポカバー入稿用.indd
i 1 1 2 2 3 3 4 4 4 5 7 8 8 9 9 10 11 13 14 15 16 17 19 ii CONTENTS 2 21 21 22 25 26 32 37 38 39 39 41 41 43 43 43 44 45 46 47 47 49 52 54 56 56 iii 57 59 62 64 64 66 67 68 71 72 72 73 74 74 77 79 81 84
これでわかるAccess2010
i 1 1 1 2 2 2 3 4 4 5 6 7 7 9 10 11 12 13 14 15 17 ii CONTENTS 2 19 19 20 23 24 25 25 26 29 29 31 31 33 35 36 36 39 39 41 44 45 46 48 iii 50 50 52 54 55 57 57 59 61 63 64 66 66 67 70 70 73 74 74 77 77
178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21
I 178 II 180 III ( ) 181 IV 183 V 185 VI 186 178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21 4 10 (
M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1
平成18年版 男女共同参画白書
i ii iii iv v vi vii viii ix 3 4 5 6 7 8 9 Column 10 11 12 13 14 15 Column 16 17 18 19 20 21 22 23 24 25 26 Column 27 28 29 30 Column 31 32 33 34 35 36 Column 37 Column 38 39 40 Column 41 42 43 44 45
1... 1... 1... 3 2... 4... 4... 4... 4... 4... 6... 10... 11... 15... 30
1 2420128 1 6 3 2 199103 189/1 1991031891 3 4 5 JISJIS X 0208, 1997 1 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1... 1... 3 2... 4... 4... 4... 4... 4... 6... 10... 11... 15... 30 1 3 5 7 6 7
5.3mg () 1 2SD 2 1.5SD 17 15 2 4 4 3 ( ) 瘙 3 嘔 気 嘔 吐 腹 痛 消 化 不 良 便 秘 4 24 p * p ** IGF-I (ng/ml) 77.12±60.19 238.97±143.60 161.85±113.30 [124.08, 199.63] (p
Microsoft Word - 内分泌・代謝分野.doc
TRH, TRH TSH, a. GH, PRL b.acth, FSH, LH, TSH GH PRL Kallmann KAL LHRH Laurence-Moon-Biedl AR Frohlich Prader-Willi Hypotonia Hypogonadism Hypomentia Obesity Sheehan DIC T4 GH 80% Laron GH IGF-I GH GH
受給者番号 ( ) 患者氏名 ( ) 告示番号 5 内分泌疾患 ( ) 年度小児慢性特定疾病医療意 書 新規申請用 2/2 インスリン CRH 負荷試験 :[ 未実施 実施 ] 実施日 :( 年 月 日 ) コルチゾール基礎値 :( )µg/dl コルチゾール頂値 :( )µg/dl ACTH 基礎
![受給者番号 ( ) 患者氏名 ( ) 告示番号 5 内分泌疾患 ( ) 年度小児慢性特定疾病医療意 書 新規申請用 2/2 インスリン CRH 負荷試験 :[ 未実施 実施 ] 実施日 :( 年 月 日 ) コルチゾール基礎値 :( )µg/dl コルチゾール頂値 :( )µg/dl ACTH 基礎](/thumbs/91/105549766.jpg "受給者番号 ( ) 患者氏名 ( ) 告示番号 5 内分泌疾患 ( ) 年度小児慢性特定疾病医療意 書 新規申請用 2/2 インスリン CRH 負荷試験 :[ 未実施 実施 ] 実施日 :( 年 月 日 ) コルチゾール基礎値 :( )µg/dl コルチゾール頂値 :( )µg/dl ACTH 基礎")
告示番号 5 内分泌疾患 ( ) 年度小児慢性特定疾病医療意 書 新規申請用 病名 1 先天性下垂体機能低下症 受給者番号受診日 受付種別 新規 1/2 ふりがな 氏名 ( 変更があった場合 ) ふりがな以前の登録氏名 生意見書記載時の年齢歳か月日性別男 女 性別未決定 出生体重 g 出生週数在胎週日出生時に住民登録をした所 ( ) 都道府県 ( ) 市区町村 現在の身長 体重 身長 cm( 体重
cm H.11.3 P.13 2 3-106-
H11.3 H.11.3 P.4-105- cm H.11.3 P.13 2 3-106- 2 H.11.3 P.47 H.11.3 P.27 i vl1 vl2-107- 3 h vl l1 l2 1 2 0 ii H.11.3 P.49 2 iii i 2 vl1 vl2-108- H.11.3 P.50 ii 2 H.11.3 P.52 cm -109- H.11.3 P.44 S S H.11.3
エクセルカバー入稿用.indd
i 1 1 2 3 5 5 6 7 7 8 9 9 10 11 11 11 12 2 13 13 14 15 15 16 17 17 ii CONTENTS 18 18 21 22 22 24 25 26 27 27 28 29 30 31 32 36 37 40 40 42 43 44 44 46 47 48 iii 48 50 51 52 54 55 59 61 62 64 65 66 67 68
III
III 1 1 2 1 2 3 1 3 4 1 3 1 4 1 3 2 4 1 3 3 6 1 4 6 1 4 1 6 1 4 2 8 1 4 3 9 1 5 10 1 5 1 10 1 5 2 12 1 5 3 12 1 5 4 13 1 6 15 2 1 18 2 1 1 18 2 1 2 19 2 2 20 2 3 22 2 3 1 22 2 3 2 24 2 4 25 2 4 1 25 2
iii iv v vi vii viii ix 1 1-1 1-2 1-3 2 2-1 3 3-1 3-2 3-3 3-4 4 4-1 4-2 5 5-1 5-2 5-3 5-4 5-5 5-6 5-7 6 6-1 6-2 6-3 6-4 6-5 6 6-1 6-2 6-3 6-4 6-5 7 7-1 7-2 7-3 7-4 7-5 7-6 7-7 7-8 7-9 7-10 7-11 8 8-1
64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k
63 3 Section 3.1 g 3.1 3.1: : 64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () 3 9.8 m/s 2 3.2 3.2: : a) b) 5 15 4 1 1. 1 3 14. 1 3 kg/m 3 2 3.3 1 3 5.8 1 3 kg/m 3 3 2.65 1 3 kg/m 3 4 6 m 3.1. 65 5
01_.g.r..
I II III IV V VI VII VIII IX X XI I II III IV V I I I II II II I I YS-1 I YS-2 I YS-3 I YS-4 I YS-5 I YS-6 I YS-7 II II YS-1 II YS-2 II YS-3 II YS-4 II YS-5 II YS-6 II YS-7 III III YS-1 III YS-2
ii iii iv CON T E N T S iii iv v Chapter1 Chapter2 Chapter 1 002 1.1 004 1.2 004 1.2.1 007 1.2.2 009 1.3 009 1.3.1 010 1.3.2 012 1.4 012 1.4.1 014 1.4.2 015 1.5 Chapter3 Chapter4 Chapter5 Chapter6 Chapter7
AccessflÌfl—−ÇŠš1
ACCESS ACCESS i ii ACCESS iii iv ACCESS v vi ACCESS CONTENTS ACCESS CONTENTS ACCESS 1 ACCESS 1 2 ACCESS 3 1 4 ACCESS 5 1 6 ACCESS 7 1 8 9 ACCESS 10 1 ACCESS 11 1 12 ACCESS 13 1 14 ACCESS 15 1 v 16 ACCESS
untitled
I...1 II...2...2 III...3...3...7 IV...15...15...20 V...23...23...24...25 VI...31...31...32...33...40...47 VII...62...62...67 VIII...70 1 2 3 4 m 3 m 3 m 3 m 3 m 3 m 3 5 6 () 17 18 7 () 17 () 17 8 9 ()
untitled
1998 6 25 ( ) 1 10 1982 10 28 37/7 1990 12 14 45/94 (WHO) 1 1989 12 8 NGO (ECE) 3 1995 10 25 ECE 1991 2 25 1992 3 17 1998 6 4 1 2 1. 2. a b c (a) (b) d 17 3. a b (a) c (b) 4. 5. 3 1. 2. 3. 4. 5. 6. 7.
「若年不安定就労・不安定住居者聞取り調査」報告書
2008 3 2006 2007 3 19 6 7 5,400 2007 4 5 19 94 1 2 2007 5 i 2007 6 12 100 100 1 2 2008 3 ii 1960 1990 iii = 1990 = = iv 5 5 v & = 2 24 = 1990 10 vi vii i iii 1 3 1.1.............................................
活用ガイド （ソフトウェア編）
(Windows 95 ) ii iii iv NEC Corporation 1999 v P A R T 1 vi P A R T 2 vii P A R T 3 P A R T 4 viii P A R T 5 ix x P A R T 1 2 3 1 1 2 4 1 2 3 4 5 1 1 2 3 4 6 5 6 7 7 1 1 2 8 1 9 1 1 2 3 4 5 6 1 2 3 4
3 5 18 3 5000 1 2 7 8 120 1 9 1954 29 18 12 30 700 4km 1.5 100 50 6 13 5 99 93 34 17 2 2002 04 14 16 6000 12 57 60 1986 55 3 3 3 500 350 4 5 250 18 19 1590 1591 250 100 500 20 800 20 55 3 3 3 18 19 1590
- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...
取 扱 説 明 書 - - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...9...11 - - - - - - - - - - - - - - - - -
困ったときのQ&A
ii iii iv NEC Corporation 1997 v P A R T 1 vi vii P A R T 2 viii P A R T 3 ix x xi 1P A R T 2 1 3 4 1 5 6 1 7 8 1 9 1 2 3 4 10 1 11 12 1 13 14 1 1 2 15 16 1 2 1 1 2 3 4 5 17 18 1 2 3 1 19 20 1 21 22 1
０１．表紙.PDF
IC CRM IT 3 i ii iii iv v vi vii viii .......................................... .................................... -0.3% t-co 2 217-4.0% +5.0 +44.6% +10.0% +5.6% 267 51.9 264 +21.8 500 2002 458 1998
無印良品 2012 自転車 カタログ
26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417
86 7 I ( 13 ) II ( )
10 I 86 II 86 III 89 IV 92 V 2001 93 VI 95 86 7 I 2001 6 12 10 2001 ( 13 ) 10 66 2000 2001 4 100 1 3000 II 1988 1990 1991 ( ) 500 1994 2 87 1 1994 2 1000 1000 1000 2 1994 12 21 1000 700 5 800 ( 97 ) 1000
活用ガイド （ソフトウェア編）
(Windows 98 ) ii iii iv v NEC Corporation 1999 vi P A R T 1 P A R T 2 vii P A R T 3 viii P A R T 4 ix P A R T 5 x P A R T 1 2 3 1 1 2 4 1 2 3 4 5 1 1 2 3 4 5 6 6 7 7 1 1 2 8 1 9 1 1 2 3 4 5 6 1 2 3 10
i
i ii iii iv v vi vii viii ix x xi ( ) 854.3 700.9 10 200 3,126.9 162.3 100.6 18.3 26.5 5.6/s ( ) ( ) 1949 8 12 () () ア イ ウ ) ) () () () () BC () () (
3 A 18 11 19 2 1 JIA 2 (JSCA) 3 4 5 6 7 8 9 10 11 12 13 14 B 4 I. (1) 18 3 29 30 33 12 18 3 542,264 22.5 62 46.3 242 149 29% 3 7 7 1 2 1 2 0.1.1 0.1.2 60 17 1 3 6 8 1 2 0.1.3 1 2 0.1.4 5 (2) (1) 0.2.2
第１部 一般的コメント
(( 2000 11 24 2003 12 31 3122 94 2332 508 26 a () () i ii iii iv (i) (ii) (i) (ii) (iii) (iv) (a) (b)(c)(d) a) / (i) (ii) (iii) (iv) 1996 7 1996 12
untitled
COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5
1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915
CRS4
I... 1 II... 1 A... 1 B... 1 C... 1 D... 2 E... 3 III... 3 A... 3 B... 4 C... 5 IV... 8 A... 8 B... 8 C... 9 D... 10 V... 11 A... 11 B... 11 C... 12 VI... 12 A... 12 B... 12 C... 12 VII... 13 ii I II A
I II III IV V
I II III IV V N/m 2 640 980 50 200 290 440 2m 50 4m 100 100 150 200 290 390 590 150 340 4m 6m 8m 100 170 250 µ = E FRVβ β N/mm 2 N/mm 2 1.1 F c t.1 3 1 1.1 1.1 2 2 2 2 F F b F s F c F t F b F s 3 3 3
200 30 984 1 1854 1713 1000 1008 ED ADL/QOL The European Working Group on Sarcopenia in Older People EWGSOP Asian Working Group for Sarcopenia AWGS D C Zhang, 2006 C Imamura, 2008 ATP Imamura, 2009 Imamura,
かんたん操作ガイド
1-2 i ii iii iv v vi vii viii 1Chapter 1-1 1-2 1-3 1-4 1-5 1-6 1-7 1 3 2 4 1-8 1-9 1-10 2Chapter 2-1 2-2 Check! 2-3 Point 2-4 Point 2-5 Point 2-6 1 a a b c 2 a b c b 2-7 c 5 3 4 6 a 2-8 b b c b 7 a c a
活用ガイド (ソフトウェア編)
ii iii iv NEC Corporation 1998 v vi PA RT 1 vii PA RT 2 viii PA RT 3 PA RT 4 ix P A R T 1 2 3 1 4 5 1 1 2 1 2 3 4 6 1 2 3 4 5 7 1 6 7 8 1 9 1 10 1 2 3 4 5 6 7 8 9 10 11 11 1 12 12 1 13 1 1 14 2 3 4 5 1
表1票4.qx4
iii iv v 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 22 23 10 11 24 25 26 27 10 56 28 11 29 30 12 13 14 15 16 17 18 19 2010 2111 22 23 2412 2513 14 31 17 32 18 33 19 34 20 35 21 36 24 37 25 38 2614
パソコン機能ガイド
PART12 ii iii iv v 1 2 3 4 5 vi vii viii ix P A R T 1 x P A R T 2 xi P A R T 3 xii xiii P A R T 1 2 3 1 4 5 1 6 1 1 2 7 1 2 8 1 9 10 1 11 12 1 13 1 2 3 4 14 1 15 1 2 3 16 4 1 1 2 3 17 18 1 19 20 1 1
パソコン機能ガイド
PART2 iii ii iv v 1 2 3 4 5 vi vii viii ix P A R T 1 x P A R T 2 xi P A R T 3 xii xiii P A R T 1 2 1 3 4 1 5 6 1 2 1 1 2 7 8 9 1 10 1 11 12 1 13 1 2 3 14 4 1 1 2 3 15 16 1 17 1 18 1 1 2 19 20 1 21 1 22
第１章 国民年金における無年金
1 2 3 4 ILO ILO 5 i ii 6 7 8 9 10 ( ) 3 2 ( ) 3 2 2 2 11 20 60 12 1 2 3 4 5 6 7 8 9 10 11 12 13 13 14 15 16 17 14 15 8 16 2003 1 17 18 iii 19 iv 20 21 22 23 24 25 ,,, 26 27 28 29 30 (1) (2) (3) 31 1 20
II (No.2) 2 4,.. (1) (cm) (2) (cm) , (
II (No.1) 1 x 1, x 2,..., x µ = 1 V = 1 k=1 x k (x k µ) 2 k=1 σ = V. V = σ 2 = 1 x 2 k µ 2 k=1 1 µ, V σ. (1) 4, 7, 3, 1, 9, 6 (2) 14, 17, 13, 11, 19, 16 (3) 12, 21, 9, 3, 27, 18 (4) 27.2, 29.3, 29.1, 26.0,
untitled
23 12 10 12:55 ~ 18:45 KKR Tel0557-85-2000 FAX0557-85-6604 12:55~13:00 13:00~13:38 I 1) 13:00~13:12 2) 13:13~13:25 3) 13:26~13:38 13:39~14:17 II 4) 13:39~13:51 5) 13:52 ~ 14:04 6) 14:05 ~ 14:17 14:18 ~
1... 1 2... 1 1... 1 2... 2 3... 2 4... 4 5... 4 6... 4 7... 22 8... 22 3... 22 1... 22 2... 23 3... 23 4... 24 5... 24 6... 25 7... 31 8... 32 9... 3
3 2620149 3 6 3 2 198812 21/ 198812 21 1 3 4 5 JISJIS X 0208 : 1997 JIS 4 JIS X 0213:2004 http://www.pref.hiroshima.lg.jp/site/monjokan/ 1... 1 2... 1 1... 1 2... 2 3... 2 4... 4 5... 4 6... 4 7... 22
1 2 1.2 1.2.1 =PAS.. =.. =.... 1% 01% ] 1.2.2 = = = = 4 (A/A 2 / /B ) 1 8 2n / 16 32 2n n 64 n 64 n ml /ml AI ml 50 5 10 0.5 0.25-0.5 30 1 30 1 0.2-0.
![1 2 1.2 1.2.1 =PAS.. =.. =.... 1% 01% ] 1.2.2 = = = = 4 (A/A 2 / /B ) 1 8 2n / 16 32 2n n 64 n 64 n ml /ml AI ml 50 5 10 0.5 0.25-0.5 30 1 30 1 0.2-0.](/thumbs/40/22237015.jpg "1 2 1.2 1.2.1 =PAS.. =.. =.... 1% 01% ] 1.2.2 = = = = 4 (A/A 2 / /B ) 1 8 2n / 16 32 2n n 64 n 64 n ml /ml AI ml 50 5 10 0.5 0.25-0.5 30 1 30 1 0.2-0.")
1 1 1 1.1 1.1.1 3 : 0: + : +0 : : } 40 40 40 = 3 35 35 (38 )? +0+7 30 35-0+0 38 38 +30 5 30 30 +20 16 16 1. [ ] 2. 3. 4. + = etc 1.1.2 Ru 1 2 1.2 1.2.1 =PAS.. =.. =.... 1% 01% ] 1.2.2 = = = = 4 (A/A 2
o 2o 3o 3 1. I o 3. 1o 2o 31. I 3o PDF Adobe Reader 4o 2 1o I 2o 3o 4o 5o 6o 7o 2197/ o 1o 1 1o
78 2 78... 2 22201011... 4... 9... 7... 29 1 1214 2 7 1 8 2 2 3 1 2 1o 2o 3o 3 1. I 1124 4o 3. 1o 2o 31. I 3o PDF Adobe Reader 4o 2 1o 72 1. I 2o 3o 4o 5o 6o 7o 2197/6 9. 9 8o 1o 1 1o 2o / 3o 4o 5o 6o
I? 3 1 3 1.1?................................. 3 1.2?............................... 3 1.3!................................... 3 2 4 2.1........................................ 4 2.2.......................................
20 15 14.6 15.3 14.9 15.7 16.0 15.7 13.4 14.5 13.7 14.2 10 10 13 16 19 22 1 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 2,500 59,862 56,384 2,000 42,662 44,211 40,639 37,323 1,500 33,408 34,472
